Lixte Biotechnology Holdings, Inc. (LIXT)

NASDAQ: LIXT · IEX Real-Time Price · USD
0.670
-0.024 (-3.46%)
Dec 7, 2022 10:20 AM EST - Market open
-3.46%
Market Cap 11.55M
Revenue (ttm) n/a
Net Income (ttm) -6.71M
Shares Out 16.65M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,910
Open 0.67
Previous Close 0.694
Day's Range 0.67 - 0.69
52-Week Range 0.43 - 4.95
Beta -0.63
Analysts n/a
Price Target n/a
Earnings Date Nov 9, 2022

About LIXT

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically ac... [Read more]

Industry Biotechnology
Founded 2005
Employees 3
Stock Exchange NASDAQ
Ticker Symbol LIXT
Full Company Profile

Financial Performance

Financial Statements

News

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Presentation to be Broadcast Wednesday December 7 at 3:30 p.m. EST/12:30 p.m.

1 week ago - Accesswire

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TIS...

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercia...

1 month ago - GlobeNewsWire

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMEN...

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, ann...

5 months ago - GlobeNewsWire

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use

5 months ago - GlobeNewsWire

Short Squeeze Stocks: RDBX, MDVL and 3 Others Experts Think Are Ready to Pop

Short squeeze stocks are in focus today following another bearish week for the markets. Here are Fintel's top short squeeze candidates.

Other symbols: HCDIMDVLCWH
6 months ago - InvestorPlace

Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop

Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.

Other symbols: ATERHCDIZYMEVERU
7 months ago - InvestorPlace

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: ATERHCDIVERUZYME
7 months ago - Benzinga

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer tr...

7 months ago - GlobeNewsWire

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered...

JERSEY CITY, N.J., April 14, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of the purchase and sale o...

7 months ago - PRNewsWire

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biote...

LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-services investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology...

7 months ago - Business Wire

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

$5.8 Million Registered Direct Offering Priced At-The-Market JERSEY CITY, N.J. , April 13, 2022  /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional executio...

7 months ago - PRNewsWire

LIXT Stock Gets 200%+ Lift, Don't Get Caught on the Way Down

LIXT stock has surged by 200% on positive pre-clinical trials news. However, it has a long way to go before its drug candidate is approved.

7 months ago - InvestorPlace

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Other symbols: ATNMPTEQLGN
7 months ago - InvestorPlace

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer tr...

7 months ago - GlobeNewsWire

Why Is Lixte Biotechnology (LIXT) Stock Up Today?

Lixte Biotechnology (LIXT) stock is rocketing higher on Tuesday after the company revealed pre-clinical results for one of its treatments. The post Why Is Lixte Biotechnology (LIXT) Stock Up Today?

7 months ago - InvestorPlace

Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers

LIXTE Biotechnology Holdings Inc (NASDAQ: LIXT) shares are trading higher after the presentation of new data from drug combinations of LIXTE's lead clinical cancer compound, LB-100. Data were shared at ...

7 months ago - Benzinga

LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Reveali...

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, an...

7 months ago - GlobeNewsWire

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB...

Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers ( loss - of - function mutations) correlates...

8 months ago - GlobeNewsWire

LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

PASADENA, CA, March 16, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer tr...

8 months ago - GlobeNewsWire

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Ca...

PASADENA, CA, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one o...

10 months ago - GlobeNewsWire

See Why Lixte Biotech Shares Trading At Over 100%?

In preclinical studies, Lixte Biotechnology Holdings Inc's (NASDAQ: LIXT) lead clinical compound, LB-100, increased the responsiveness of diverse cancers to immunotherapy.  The data reported that treatm...

11 months ago - Benzinga

Lixte Biotechnology's LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Resp...

Outside research shows that in models of colorectal, triple- negative breast and pancreatic cancer ,  LB- 100 induces molecular changes that render the cancers more vulnerable to immunotherapy

11 months ago - GlobeNewsWire

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE'S TRIAL TO DETE...

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacolog...

1 year ago - GlobeNewsWire

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrec...

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings , Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of th...

1 year ago - GlobeNewsWire

Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Fe...

A series of recent pre - clinical reports demonstrat e s LB-100's effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition

1 year ago - GlobeNewsWire